Stem cell engraftment and survival in the ischemic heart |
| |
| Authors: | Wu Kai Hong Mo Xu Ming Han Zhong Chao Zhou Bin |
| |
| Affiliation: | aDepartment of Cardiothoracic Surgery, Nanjing Children‘s Hospital, Nanjing Medical University, Nanjing, China;bNational Research Center for Stem Cell Engineering and Technology, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China;cInstitute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China |
| |
| Abstract: | Cellular therapy has emerged as a potentially novel treatment for severe ischemic heart disease, and there is increasing evidence that stem cell transplantation may improve the perfusion and contractile function of ischemic myocardium. However, the problem of poor donor cell engraftment and survival in ischemic myocardium limits the successful use of cellular therapy for treating ischemic heart disease. This review discusses the state-of-the-art understanding of the low level of cell engraftment and cell survival after transplantation into the ischemic heart, with a focus on the approaches that have been investigated for supporting and improving the survival and engraftment of transplanted cells in this setting. |
| |
| Keywords: | Abbreviations and Acronyms: ADSCs, adipose derived stem cells Ang-1, angiopoietin-1 BM cells, bone marrow cells CABG, coronary artery bypass grafting ES cells, embryonic stem cells FGF-2, fibroblast growth factor 2 GMP, good manufacturing practice HIF-1α, hypoxia-inducible factor 1alpha I/R:, ischemia/reoxygenation ICD, cardioverter-defibrillator IGF, insulin-like growth factor MI, myocardial infarction MSCs, mesenchymal stem cells OPCABG, off-pump coronary artery bypass grafting PBS, phosphate-buffered saline SDF-1, stromal cell-derived factor 1 VEGF, vascular endothelial growth factor |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
